Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Solvonis Therapeutics completes acquisition of Awakn Life Sciences
Solvonis Therapeutics PLC (LSE:SVNS) has now completed its acquisition of Awakn Life Sciences. The transaction covers multiple assets, including SVNS-001, a Phase 3 therapy for Alcohol Use Disorder.» Mehr auf proactiveinvestors.co.uk
CSE Bulletin: Delist - Awakn Life Sciences Corp. (AWKN)
Toronto, Ontario--(Newsfile Corp. - Le 27 mai/May 2025) - Awakn Life Sciences Corp. ("Awakn" or the "Company"), is pleased to announce, further to its press releases dated February 27, 2025, April 11, 2025 and April 23, 2025, that Solvonis Therapeutics plc ("Solvonis") has acquired all of the outstanding common shares in the capital of the Company (the "Common Shares"), all outstanding restricted share units (the "RSUs") in the capital of the Company, and all outstanding deferred share units (the "DSUs") in the capital of the Company (the "Transaction"), pursuant to an arrangement (the "Arrangement"). Awakn will be delisted market close on May 27, 2025.» Mehr auf newsfilecorp.com
Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), is pleased to announce, further to its press releases dated February 27, 2025, April 11, 2025 and April 23, 2025, that Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis") has acquired all of the outstanding common shares in the capital of the Company (the "Common Shares"), all outstanding restricted share units (the "RSUs") in the capital of the Company, and all outstanding deferred share units (the "DSUs") in the capital of the Company (the "Transaction"), pursuant to an arrangement (the "Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) carried out pursuant to an arrangement agreement dated February 22, 2025 between the Company and Solvonis (the "Arrangement Agreement"). Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding Common Shares will receive 46.67 ordinary shares in the capital of Solvonis (each, a "Solvonis Share") for each one (1) Common Share held.» Mehr auf newsfilecorp.com

Unternehmenszahlen

Im letzten Quartal hatte Awakn Life Sciences einen Umsatz von 2,42k€ und ein Nettoeinkommen von −248,01k€

(EUR)	Okt. 2024	YOY
Umsatz	+2,42k	-
Bruttoeinkommen	+2,42k	-
Nettoeinkommen	−248,01k	-
EBITDA	−308,19k	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+2,36 Mio€
Anzahl Aktien	41,66 Mio
52 Wochen-Hoch/Tief	+0,12€ - +0,0424€
Dividenden	Nein
Beta	2,6
KGV (PE Ratio)	−0,28
KGWV (PEG Ratio)	0,00
KBV (PB Ratio)	+2,97
KUV (PS Ratio)	+2,58

Unternehmensprofil

Awakn Life Sciences Corp. ist ein Biotechnologieunternehmen, das sich mit der Erforschung, Entwicklung, dem Betrieb und der Bereitstellung von psychedelischen Therapeutika zur Behandlung von Sucht und anderen psychischen Erkrankungen in Großbritannien und Europa befasst. Der Hauptsitz des Unternehmens befindet sich in Toronto, Kanada.